Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
- Written by PR Newswire
Collaboration will bring together Umoja's iCIL platform and IASO's chimeric antigen receptors to create the next generation of broadly accessible, readily available cell therapies in indications that are significantly underserved by today's standards of care.
SEATTLE, SAN JOSE, Calif., SHANGHAI and NANJING, China, Nov. 21, 2022 /PRNewswire/ --...
